van Spriel AB - Search Results

1

Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma.

van Spriel AB, van Ojik HH, Bakker A, Jansen MJ, van de Winkel JG. van Spriel AB, et al. Among authors: van ojik hh, van de winkel jg. Blood. 2003 Jan 1;101(1):253-8. doi: 10.1182/blood.V101.1.253. Blood. 2003. PMID: 12485936 Free article.

2

Mac-1 (CD11b/CD18) as accessory molecule for Fc alpha R (CD89) binding of IgA.

Van Spriel AB, Leusen JH, Vilé H, Van De Winkel JG. Van Spriel AB, et al. Among authors: van de winkel jg. J Immunol. 2002 Oct 1;169(7):3831-6. doi: 10.4049/jimmunol.169.7.3831. J Immunol. 2002. PMID: 12244179

3

Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18).

van Egmond M, van Vuuren AJ, Morton HC, van Spriel AB, Shen L, Hofhuis FM, Saito T, Mayadas TN, Verbeek JS, van de Winkel JG. van Egmond M, et al. Among authors: van spriel ab, van vuuren aj, van de winkel jg. Blood. 1999 Jun 15;93(12):4387-94. Blood. 1999. PMID: 10361137 Free article.

4

Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation.

van Spriel AB, Leusen JH, van Egmond M, Dijkman HB, Assmann KJ, Mayadas TN, van de Winkel JG. van Spriel AB, et al. Among authors: van egmond m, van de winkel jg. Blood. 2001 Apr 15;97(8):2478-86. doi: 10.1182/blood.v97.8.2478. Blood. 2001. PMID: 11290613 Free article.

5

FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.

Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG. Valerius T, et al. Among authors: van spriel ab, van den herik oudijk ie, van de winkel jg. Blood. 1997 Dec 1;90(11):4485-92. Blood. 1997. PMID: 9373259 Free article.

6

Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils.

van Spriel AB, van den Herik-Oudijk IE, van Sorge NM, Vilé HA, van Strijp JA, van de Winkel JG. van Spriel AB, et al. Among authors: van strijp ja, van sorge nm, van den herik oudijk ie, van de winkel jg. J Infect Dis. 1999 Mar;179(3):661-9. doi: 10.1086/314643. J Infect Dis. 1999. PMID: 9952373

7

Immunotherapeutic perspective for bispecific antibodies.

van Spriel AB, van Ojik HH, van De Winkel JG. van Spriel AB, et al. Among authors: van ojik hh, van de winkel jg. Immunol Today. 2000 Aug;21(8):391-7. doi: 10.1016/s0167-5699(00)01659-5. Immunol Today. 2000. PMID: 10916142 Review.

8

Targeting to Fcgamma receptors, but not CR3 (CD11b/CD18), increases clearance of Bordetella pertussis.

Hellwig SM, van Oirschot HF, Hazenbos WL, van Spriel AB, Mooi FR, van De Winkel JG. Hellwig SM, et al. Among authors: van spriel ab, van oirschot hf, van de winkel jg. J Infect Dis. 2001 Mar 15;183(6):871-9. doi: 10.1086/319266. Epub 2001 Feb 13. J Infect Dis. 2001. PMID: 11237803

9

IgA and the IgA Fc receptor.

van Egmond M, Damen CA, van Spriel AB, Vidarsson G, van Garderen E, van de Winkel JG. van Egmond M, et al. Among authors: van spriel ab, van garderen e, van de winkel jg. Trends Immunol. 2001 Apr;22(4):205-11. doi: 10.1016/s1471-4906(01)01873-7. Trends Immunol. 2001. PMID: 11274926 Review.

10

Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).

van Egmond M, van Spriel AB, Vermeulen H, Huls G, van Garderen E, van de Winkel JG. van Egmond M, et al. Among authors: van spriel ab, van garderen e, van de winkel jg. Cancer Res. 2001 May 15;61(10):4055-60. Cancer Res. 2001. PMID: 11358825

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

82 results

Search Page